{"status": "ok", "totalResults": 184, "articles": [{"source": {"id": "al-jazeera-english", "name": "Al Jazeera English"}, "author": "Al Jazeera", "title": "India bans hundreds of combination drugs", "description": "Government outlaws 328 drugs to combat medicine misuse and rising antibiotic resistance.", "url": "https://www.aljazeera.com/news/2018/09/india-bans-hundreds-combination-drugs-180913085744857.html", "urlToImage": "https://www.aljazeera.com/mritems/Images/2018/9/13/21551545769d41bbae79f1cdcdbd2ee5_18.jpg", "publishedAt": "2018-09-13T10:39:01Z", "content": "The Indian government has banned 328 combination drugs in a blow to both domestic and foreign pharmaceutical firms, but the ban has been cheered by health activists worried about growing antibiotic resistance due to the misuse of medicines. The Indian governm\u2026 [+1954 chars]"}, {"source": {"id": null, "name": "Pib.nic.in"}, "author": null, "title": "Cabinet approves MoU between India and Uzbekistan on cooperation in pharmaceutical sector", "description": "The Union Cabinet chaired by Prime Minister Shri Narendra Modi has approved the signing of a Memorandum of Understanding (MoU) between India and Uzbekistan for increased cooperation in the areas of Trade, Industry, and Research & Development of Pharmaceutical\u2026", "url": "http://pib.nic.in/newsite/PrintRelease.aspx?relid=183723", "urlToImage": null, "publishedAt": "2018-09-26T10:22:00Z", "content": "The Union Cabinet chaired by Prime Minister Shri Narendra Modi has approved the signing of a Memorandum of Understanding (MoU) between India and Uzbekistan for increased cooperation in the areas of Trade, Industry, and Research &amp; Development of Pharmaceut\u2026 [+932 chars]"}, {"source": {"id": null, "name": "Pib.nic.in"}, "author": null, "title": "Cabinet approves MoU between India and Uzbekistan on cooperation for establishment of Uzbek-Indian Free Pharmaceutical Zone in the Andijan region of Uzbekistan", "description": "The Union Cabinet chaired by Prime Minister Shri Narendra Modi has approved the Memorandum of Understanding (MoU) between India and Uzbekistan for establishment of the Uzbek-Indian Free Pharmaceutical Zone in the Andijan Region of Uzbekistan.", "url": "http://pib.nic.in/newsite/PrintRelease.aspx?relid=183729", "urlToImage": null, "publishedAt": "2018-09-26T10:26:00Z", "content": "The Union Cabinet chaired by Prime Minister Shri Narendra Modi has approved the Memorandum of Understanding (MoU) between India and Uzbekistan for establishment of the Uzbek-Indian Free Pharmaceutical Zone in the Andijan Region of Uzbekistan. The MoU will be \u2026 [+796 chars]"}, {"source": {"id": null, "name": "Forbes.com"}, "author": "Russell Flannery, Forbes Staff, Russell Flannery, Forbes Staff https://www.forbes.com/sites/russellflannery/", "title": "Fosun Pharma Sees \"Huge\" Opportunities in India, Southeast Asia, Africa", "description": "\"China has grown tremendously in the past four decades; our management team believes that we can provide valuable experience contribute to another growth miracle in those markets.\"", "url": "https://www.forbes.com/sites/russellflannery/2018/09/17/fosun-pharma-sees-huge-opportunities-in-india-southeast-asia-africa/", "urlToImage": "https://thumbor.forbes.com/thumbor/600x315/https%3A%2F%2Fi.forbesimg.com%2Fmedia%2Fassets%2Fforbes_1200x1200.jpg", "publishedAt": "2018-09-18T03:29:00Z", "content": "Fosun International, led by Shanghai billionaire Guo Guangchang, has long made a name for itself through international partnerships and investments.&amp;nbsp; Fosun Pharma, Fosun's pharmaceutical arm, is also stepping up its international ties, recently setti\u2026 [+7496 chars]"}, {"source": {"id": "the-times-of-india", "name": "The Times of India"}, "author": null, "title": "Have you been taking fake medicines?", "description": "Simple initiatives to battle the issue of counterfeit drugs", "url": "https://timesofindia.indiatimes.com/how-are-e-pharmacies-beating-the-fake-drugs-issue-in-india/articleshow/65936562.cms", "urlToImage": "https://static.toiimg.com/photo/msid-65936852/65936852.jpg?118537", "publishedAt": "2018-09-26T06:24:07Z", "content": "According to World Health Organization, one out of ten medicines in India are fake. The Associated Chambers of Commerce and Industry of India (ASSOCHAM) has stated that counterfeit drugs constitute 25% of domestic medicines market in India, in the research pa\u2026 [+2769 chars]"}, {"source": {"id": null, "name": "Pib.nic.in"}, "author": null, "title": "Ambitious, transformative vision make India a safe destination for investments: Vice President", "description": "The Vice President of India, Shri M. Venkaiah Naidu has said that the ambitious, transformative vision that is making India one of the most favourite investment destinations in the word. He was addressing the India-Malta Business Forum in the presence of the \u2026", "url": "http://pib.nic.in/newsite/PrintRelease.aspx?relid=183529", "urlToImage": null, "publishedAt": "2018-09-18T08:01:00Z", "content": "The Vice President of India, Shri M. Venkaiah Naidu has said that the ambitious, transformative vision that is making India one of the most favourite investment destinations in the word. He was addressing the India-Malta Business Forum in the presence of the \u2026 [+5489 chars]"}, {"source": {"id": null, "name": "Indianexpress.com"}, "author": "PTI", "title": "Centre bans 328 combination drugs in setback for pharma companies", "description": "The president of the Indian Drug Manufacturers' Association said the order would have an impact on a market worth an estimated 16 billion rupees a year for such drugs, which are produced by both small and large pharma companies.", "url": "https://indianexpress.com/article/business/business-others/centre-bans-328-combination-drugs-in-setback-for-pharma-companies-5354509/", "urlToImage": "https://images.indianexpress.com/2017/11/drugs-7592.jpg?w=759", "publishedAt": "2018-09-13T09:13:42Z", "content": "By: PTI | New Delhi | Published: September 13, 2018 2:43:42 pm Combination drugs are used to improve patients\u2019 compliance, as it is easier to get patients to take one drug rather than several. (Representational image) The Indian government has banned 328 comb\u2026 [+2241 chars]"}, {"source": {"id": null, "name": "Indianexpress.com"}, "author": "Deepak Patel", "title": "Rework trade margin plan on medical devices: PMO to Niti Aayog", "description": "Association of Indian Medical Device Industry (AIMED), which represents Indian medical device companies, wrote a letter to PMO on August 27 stating that \u201cnot only retailers and hospitals\u201d but the importers too \u201cenjoy irrational margins in the supply chain\u201d.", "url": "https://indianexpress.com/article/business/economy/rework-trade-margin-plan-on-medical-devices-pmo-to-niti-aayog-5358410/", "urlToImage": "https://images.indianexpress.com/2018/08/modi-delhi-ie.jpg?w=759", "publishedAt": "2018-09-15T19:25:00Z", "content": "Written by Deepak Patel | New Delhi | Published: September 16, 2018 12:55:00 am The Niti Aayog has been asked, therefore, to rework on their trade margin model and bring it back. The Prime Minister\u2019s Office (PMO) has rejected the Niti Aayog proposal to implem\u2026 [+3344 chars]"}, {"source": {"id": "the-times-of-india", "name": "The Times of India"}, "author": "Rupali Mukherjee", "title": "Needle, syringe manufacturers seek price cap", "description": "Manufacturers have written to the National List of Essential Medicines (NLEM) committee to include all categories of syringes and needles in the 'price cap' list. If accepted, this would be the third medical device, after cardiac stents and orthopaedic implan\u2026", "url": "https://timesofindia.indiatimes.com/city/mumbai/in-a-first-syringe-needle-manufacturers-ask-govt-to-impose-price-cap/articleshow/65941411.cms", "urlToImage": "https://static.toiimg.com/thumb/msid-65941711,width-1070,height-580,imgsize-118135,resizemode-6,overlay-toi_sw,pt-32,y_pad-40/photo.jpg", "publishedAt": "2018-09-24T19:30:00Z", "content": "MUMBAI: In a move which could benefit patients, syringe and needle manufacturers have urged government to impose price caps and curb unethical practices and overcharging by hospitals. This is one of the first such instances when an industry has itself sought \u2026 [+2899 chars]"}, {"source": {"id": "the-hindu", "name": "The Hindu"}, "author": "Ranjana Smetacek", "title": "Lessons from a neighbour", "description": "The world has witnessed a transformation in health care during the last century. Prescription drugs have helped wipe out diseases and revolutionise cu", "url": "https://www.thehindu.com/sci-tech/health/lessons-from-a-neighbour/article25017317.ece", "urlToImage": "https://www.thehindu.com/sci-tech/health/z9jrwk/article18788680.ece/ALTERNATES/LANDSCAPE_615/ANTIBIOTICS", "publishedAt": "2018-09-22T17:28:34Z", "content": "The world has witnessed a transformation in health care during the last century. Prescription drugs have helped wipe out diseases and revolutionise cures, which has resulted in resulting in better treatment outcomes, more effective pain management and people \u2026 [+4441 chars]"}, {"source": {"id": "reuters", "name": "Reuters"}, "author": "Reuters Editorial", "title": "India bans 328 combination drugs in setback for pharma companies", "description": "The Indian government has banned 328 combination drugs in a blow to both domestic and foreign pharmaceutical firms, but the ban has been cheered by health activists worried about growing antibiotic resistance due to the misuse of medicines.", "url": "https://www.reuters.com/article/us-india-health-drugs/india-bans-328-combination-drugs-in-setback-for-pharma-companies-idUSKCN1LT155", "urlToImage": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "publishedAt": "2018-09-13T08:39:28Z", "content": "NEW DELHI (Reuters) - The Indian government has banned 328 combination drugs in a blow to both domestic and foreign pharmaceutical firms, but the ban has been cheered by health activists worried about growing antibiotic resistance due to the misuse of medicin\u2026 [+2034 chars]"}, {"source": {"id": "the-hindu", "name": "The Hindu"}, "author": "Special Correspondent", "title": "NORD plans to set up assembling plant in State", "description": "Markets in India have big scope: MD", "url": "https://www.thehindu.com/news/cities/Visakhapatnam/nord-plans-to-set-up-assembling-plant-in-state/article24897488.ece", "urlToImage": "https://www.thehindu.com/static/theme/default/base/img/og-image.jpg", "publishedAt": "2018-09-07T19:31:40Z", "content": "Mechanical and electrical solutions manufacturer NORD Drive Systems, a subsidiary of Germany-based Getriebebau NORD, organised an end-user service conference and a road show, in association with the AP Chambers of Commerce and Industry Federation (APCCIF) her\u2026 [+1092 chars]"}, {"source": {"id": null, "name": "Moneycontrol.com"}, "author": null, "title": "Lupin to train over 1,000 graduates for pharma industry by 2020", "description": "Lupin has launched its #39;Learn and Earn#39; initiative in which candidate who has passed Standard 12 in the science stream with a minimum of 50 percent marks but are facing financial constraints are taken for three-year-long course during which they are pai\u2026", "url": "https://www.moneycontrol.com/news/business/lupin-to-train-over-1000-graduates-for-pharma-industry-by-2020-2924881.html", "urlToImage": "https://static-news.moneycontrol.com/static-mcnews/2018/07/Lupin-770x433.jpg", "publishedAt": "2018-09-06T10:46:05Z", "content": "Pharmceutical giant, Lupin Limited expects to train more than 1,000 under graduates into pharma professionals by the year 2020 under its Learn and Earn Initiative, a senior company official said today. Lupin has launched its 'Learn and Earn' initiative in whi\u2026 [+1850 chars]"}, {"source": {"id": null, "name": "Nature.com"}, "author": null, "title": "Gravity glitch, biodefence plan and an asteroid first", "description": "The week in science: 21\u201327 September 2018.", "url": "https://www.nature.com/articles/d41586-018-06780-9?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+nature%2Frss%2Fcurrent+%28Nature+-+Issue%29", "urlToImage": "https://media.nature.com/lw1024/magazine-assets/d41586-018-06780-9/d41586-018-06780-9_16147192.jpg", "publishedAt": "2018-09-26T00:00:00Z", "content": "SPACE Japan mission makes asteroid history Japans asteroid mission Hayabusa2 has become the first to land moving rovers on the surface of an asteroid. On 22 September, the Japan Aerospace Exploration Agency (JAXA) confirmed that the missions twin rovers, call\u2026 [+8176 chars]"}, {"source": {"id": null, "name": "Nature.com"}, "author": null, "title": "Gravity glitch, biodefence plan and an asteroid first", "description": "The week in science: 21\u201327 September 2018.", "url": "https://www.nature.com/articles/d41586-018-06780-9", "urlToImage": "https://media.nature.com/lw1024/magazine-assets/d41586-018-06780-9/d41586-018-06780-9_16147192.jpg", "publishedAt": "2018-09-26T00:00:00Z", "content": "SPACE Japan mission makes asteroid history Japans asteroid mission Hayabusa2 has become the first to land moving rovers on the surface of an asteroid. On 22 September, the Japan Aerospace Exploration Agency (JAXA) confirmed that the missions twin rovers, call\u2026 [+8176 chars]"}, {"source": {"id": null, "name": "Insightsonindia.com"}, "author": "InsightsIAS", "title": "Insights into Editorial: Biosimilars need huge investments, longer timelines", "description": "Insights into Editorial: Biosimilars need huge investments, longer timelines What are Biosimilars? A biosimilar is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company. Biosimilars are \u2026", "url": "http://www.insightsonindia.com/2018/09/07/insights-into-editorial-biosimilars-need-huge-investments-longer-timelines/", "urlToImage": "http://www.insightsonindia.com/wp-content/uploads/2018/09/editorial-2.jpg", "publishedAt": "2018-09-07T03:41:45Z", "content": "Insights into Editorial: Biosimilars need huge investments, longer timelines What are Biosimilars? A biosimilar is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company. Biosimilars are \u2026 [+5142 chars]"}, {"source": {"id": "bbc-news", "name": "BBC News"}, "author": "https://www.facebook.com/bbcnews", "title": "'They were not comfortable about hiring a woman'", "description": "When Kiran Mazumdar-Shaw couldn't get a job as a brewer because she was a woman, she set up a drugs business that is now worth $5.6bn.", "url": "https://www.bbc.co.uk/news/business-45547352", "urlToImage": "https://ichef.bbci.co.uk/news/1024/branded_news/58DD/production/_103494722_boss1.jpg", "publishedAt": "2018-09-23T23:24:49Z", "content": "Image copyright Getty Images Image caption Kiran Mazumdar-Shaw is India's richest self-made woman The BBC's weekly The Boss series profiles business leaders from around the world. This week we speak to Kiran Mazumdar-Shaw, founder of Indian pharmaceutical com\u2026 [+5765 chars]"}, {"source": {"id": "the-times-of-india", "name": "The Times of India"}, "author": "Jimeet Modi", "title": "'Towards correction and selective profit taking'", "description": "Uncertainty is likely to persist and the downward drift might not ease anytime soon.", "url": "https://economictimes.indiatimes.com/markets/stocks/news/journey-towards-correction-begins-its-time-for-selective-profit-taking/articleshow/65729453.cms", "urlToImage": "https://img.etimg.com/thumb/msid-65729478,width-1070,height-580,imgsize-53614,overlay-etmarkets/photo.jpg", "publishedAt": "2018-09-08T05:33:34Z", "content": "Mr Market finally made a top during the week gone by and started correcting in response to the local and global tailwinds, primarily due to a strengthening dollar, growing current account deficit, inflationary expectations, global tightening and worsening geo\u2026 [+3224 chars]"}, {"source": {"id": "the-hindu", "name": "The Hindu"}, "author": "N. RAVI KUMAR", "title": "Pharma tech upgrade scheme to get financial partner soon", "description": "SMEs will be get interest subvention upto 6% under PTUAS", "url": "https://www.thehindu.com/news/national/telangana/pharma-tech-upgrade-scheme-to-get-financial-partner-soon/article24958075.ece", "urlToImage": "https://www.thehindu.com/static/theme/default/base/img/og-image.jpg", "publishedAt": "2018-09-15T18:08:33Z", "content": "The Department of Pharmaceuticals will soon initiate the process to select a financial institution for implementing the Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS) for small and medium enterprises. Expression of interest to select the publ\u2026 [+2506 chars]"}, {"source": {"id": null, "name": "Forbes.com"}, "author": "Susan Adams, Forbes Staff, Susan Adams, Forbes Staff https://www.forbes.com/sites/susanadams/", "title": "An Expert List Of The World's Best Universities", "description": "The University of Oxford takes the No. 1 spot for the third year running on a ranking of the world\u2019s best universities released today by Times Higher Education, a UK-based publication that tracks the higher ed market. The University of Cambridge is No. 2 and \u2026", "url": "https://www.forbes.com/sites/susanadams/2018/09/26/an-expert-list-of-the-worlds-best-universities/", "urlToImage": "https://thumbor.forbes.com/thumbor/600x315/https%3A%2F%2Fblogs-images.forbes.com%2Fthumbnails%2Fblog_978%2Fpt_978_19607_o.jpg%3Ft%3D1537966867", "publishedAt": "2018-09-26T13:01:00Z", "content": "Share to facebook Share to twitter Share to linkedin Mob Quad is a four-sided group of buildings from the 13th and 14th centuries in Merton College, Oxford. The University of Oxford, the oldest university in the English-speaking world, takes the No. 1 spot fo\u2026 [+9487 chars]"}]}